Tivantinib, a selective HGFR tyrosine kinase inhibitor, showed promising results in advanced hepatocellular carcinoma and non-small-cell lung carcinoma, especially in HGFR-overexpressing subgroups [35,38]. This evidence concerns the gene MET and non-small cell lung carcinoma.